



Janet T. Mills
Governor

STATE OF MAINE
Maine Prescription Drug Affordability Board
61 State House Station
Augusta, ME 04333-0061

Noah Nesin
Chair

Maine Prescription Drug Affordability Board
Tuesday March 17, 2020 @ 9:00 am
Zoom Meeting

Council members in attendance: Peter Hayes, Frank Johnson, Kenneth Mcall III, Noah Nesin, Jennifer Reck, Julia Redding, Rhonda Selvin & Susan Wehry
(Total = 8)

Council members absent: None
(Council seat 0 vacant)

Others Present:

Department of Administrative & Financial Services: Heather Perreault

Employee Health & Benefits: Kurt Caswell & Roberta Leonard

Office of Policy and Legal Analysis: Colleen McCarthy

Maine Health Data Organization: Karynlee Harrington

Agenda Item	Discussion	Action/Next Steps
I. Call to Order (9:02 am)	Noah Nesin called the meeting to order	
II. Introductions	<ul style="list-style-type: none"> Board member introductions and backgrounds / bios 	
III. Review enabling legislation to determine scope of work & charge to the Board <i>Colleen McCarthy – Office of Policy and Legal Analysis</i>	Discussion highlights below: <ul style="list-style-type: none"> Look at verity of purposed 1162- adopt rules at the federal level, pharmacy LD1540 management law went in to effect in January the State may have seen the impact of that law. Precaution drug affordability board - broader focus with a wide range of looking at prescription drug. To focus on establishing affordable drugs for entities. Consider spending to develop recommendations to develop methods for members of the public to be able to afford drug cost. Look at other States, negotiating rebates to meet funding targets. Board need to annual report to the legislature. Report recommendations for their consideration. 	



Janet T. Mills
Governor

STATE OF MAINE
Maine Prescription Drug Affordability Board
61 State House Station
Augusta, ME 04333-0061

Noah Nesin
Chair

	<ul style="list-style-type: none"> • How would the advisory panel choose who is on the AC: Legislation set for 12 members advisory council intended to adviser on spending targets and meeting them. Representatives of Government and State departments. • Background why only public pay: Committee was interested in and looking at reimbursement rate develop consensus on legislation narrow on public payer, level of control. ERISA guide focus on public payers, as a pilot program in a sense. • Fair amount of resistance PM that operate in the State: addressing each of the areas • Add Maryland experience: MD process was similar in starting with a broader scope, moving on to private payers in coming years. Board in MD has a different charge legislature approved focused on drug pricing and setting limits. Roll out slowly over time. Jennifer Reck will provide a link. 	
<p>IV. Discuss potential effect of LD 2010 <i>Colleen McCarthy – Office of Policy and Legal Analysis</i></p>	<p>Discussion highlights:</p> <ul style="list-style-type: none"> • Intensive amended in committee original legislation appealed the board and shifted functions on over all charge functions. Committee pushed back on providers on health care spending targets at an administrative level. Steak holders have input in the committee. • Analyze health care with the State. • Authorized the Office of Affordability to hire staffing to assist with the board. • Work with existing data and how that relates with the quality of care. • Monitor what's happening in other States. • Task on improving Health care in Maine and do annual reporting. • How other state address spending and hear about trends with a public format. 	<p>Colleen McCarthy will email a copy of the legislation to Heather Perreault.</p>



Janet T. Mills
Governor

STATE OF MAINE
Maine Prescription Drug Affordability Board
61 State House Station
Augusta, ME 04333-0061

Noah Nesin
Chair

	<ul style="list-style-type: none"> • Legislative oversight committee and advisory councils and file an annual report. Efforts in MA do a similar thing. • One element of proposed legislation, LD 2110. Legislation will consider this but, with COVID-19 the session will be ending soon. Legislation may wait to pass/amend when they meet next. Does not think an amendment will take place. Maybe some changes on funding and staffing. Requesting 2 more staff members. Funding can be unpredictable 	
<p>V. Discuss information & data requirements Karynlee Harrington – Maine Health Data Organization</p>	<p>Discussion highlights:</p> <ul style="list-style-type: none"> • MHDO serves at the pleasure of the board of directors, Governor appoints board of directors created in 1995. 13 members currently. • MHDO Purpose - create and maintain a useful, objective, reliable and comprehensive health information data warehouse that is used to improve the health of Maine citizens and <i>to promote the transparency of the cost and quality of healthcare including prescription drug cost information, in the State of Maine by procedure, payer facility and provider</i> - NEW • Website compareME: https://www.comparemaine.org/?page=rx-cost • MHDO Data sets and timelines: People that take data and turn it into information. <i>Asked to look at the average payment for out of pocket cost of insulin -example.</i> Annual report due 11/2020 • Data vendors - Human service research institute (HSRI) • Commercial insurance 2009-2018 percentage has increased 2009 23% 2018 36% available on website, can select a date range. Update on a regular basis. • Public Law Chapter 406- By December 1, 2018 and annually thereafter, the MHDO must provide a report containing the following information about prescription drugs, both brand name and generic. Does not take into account rebates. 	



Janet T. Mills
Governor

STATE OF MAINE
Maine Prescription Drug Affordability Board
61 State House Station
Augusta, ME 04333-0061

Noah Nesin
Chair

	<ul style="list-style-type: none"> • Public Law Chapter 470- An Act to Further Expand Drug Price Transparency - New Law in 2019 with requirements for MHDO to: <ul style="list-style-type: none"> ○ Develop a data submission rule prior to April 1, 2020 to collect pricing information from manufactures, pharmacy benefit managers and wholesale distributors. ○ MHDO Rule Chapter 570 Uniform reporting system for prescription drug price data sets, adopted 2/4/20 ○ Confidentiality Provision • Annual report will be posted on website after November 1, 2020 • Believe a shift from brand name to generic can take place. 	
VI. Other Business	Discussion highlights:	
a. Establish expectations for Advisory Council	<ul style="list-style-type: none"> • Kurt Caswell stated the State of Maine is working on defining those roles. 	
b. Plan next steps	<ul style="list-style-type: none"> • Hold off for more framing before defining 	
c. Establish a regular meeting schedule	<ul style="list-style-type: none"> • Required to meet quarterly. 	Peter Hayes made a motion to meet as early as next month. Susan Wehry seconded.
d. Review and sign conflict of interest statements	<ul style="list-style-type: none"> • Heather Perreault will email out to the group. 	Group to email completed forms to Heather Perreault.
VII. Adjourn (11:00 am)		

Next meeting: TBD